We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Effective Prognostic Marker Identified for Ovarian Cancer

By LabMedica International staff writers
Posted on 20 Aug 2014
Print article
Image: Histopathology of high-grade serous ovarian carcinoma (Photo courtesy of Dr. Ed Uthman, MD).
Image: Histopathology of high-grade serous ovarian carcinoma (Photo courtesy of Dr. Ed Uthman, MD).
High-grade serous ovarian carcinoma (HG- SOC) is the most prevalent of epithelial ovarian cancers and remains poorly understood due to a lack of biomarkers identified for clinical use, for diagnosis, or for prognosis of patient survival rates.

The application of bioinformatics analysis on cancer genomics data has enabled the identification genes whose mutation status could be used for prognosis and development of personalized treatment for HG-SOC, which is the most lethal ovarian cancers, with only 30% patients surviving more than five years after diagnosis.

Scientists at the Agency for Science, Technology and Research (A*STAR; Singapore) analyzed data from 334 HG-SOC patients logged in the Cancer Genome Atlas (TCGA; Bethesda, MD, USA). The sequences were generated based on either Illumina (San Diego, CA, USA) or ABI SOLID sequencing technologies (Applied Biosystems; Carlsbad, CA, USA).

The team identified the gene, Checkpoint Kinase 2 (CHEK2), as an effective prognostic marker of patient survival. HG-SOC patients with mutations in this gene succumbed to the disease within five years of diagnosis, possibly because CHEK2 mutations were associated with poor response to existing cancer therapies. Mortality after diagnosis currently remains high, as patients receive similar treatment options of chemotherapy and radiotherapy despite the diverse nature of tumor cells within tumors and across different tumor samples. With these findings, personalized medicine for ovarian cancer could be developed, with targeted treatment that would be optimized for subgroups of patients.

Sir David Philip Lane, FRS, FRSE FRCPath, the chief scientist at A*STAR, said, “These findings show how the various research institutes at A*STAR offer their expertise in developing new approaches to examine different aspects of the same disease that have not been successfully studied before, such as ovarian cancer. The diverse capabilities and knowledge of our scientists allows us to investigate diseases holistically, from diagnosis to treatment.” The study was published on July 15, 2014, in the journal Cell Cycle.

Related Links:

Agency for Science, Technology and Research
The Cancer Genome Atlas
Illumina



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.